Crescent Biopharma (CBIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $11.84, -5.13% vs the prior close of $12.48.
- Volume 208.15K shares, 0.6x its 50-day average (light).
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
CBIO slides 5.1% to $11.84, a 6-month low, 5 down days in a row. Closed at $11.84, -5.13% vs the prior close of $12.48. Day range $11.78–$12.73, opened at $12.73.
CBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CBIO slides 5.1% to $11.84, a 6-month low, 5 down days in a row
- Closed at $11.84, -5.13% vs the prior close of $12.48. Day range $11.78–$12.73, opened at $12.73.
- Volume was 208.15K shares, 0.6x its 50-day average of 373.94K — lighter than usual.
- Price is -27.7% vs its 50-day average ($16.37) and -25.0% vs its 200-day average ($15.79).
- 52-week range $8.72–$27.41; today's close sits at 17% of that range, 56.8% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — CBIO dips 0.8% to $12.48, a 6-month low, 4 down days in a row
- Closed at $12.48, -0.79% vs the prior close of $12.58. Day range $12.31–$13.19, opened at $12.62.
- Volume was 295.90K shares, 0.8x its 50-day average of 371.70K.
- Price is -24.2% vs its 50-day average ($16.46) and -21.0% vs its 200-day average ($15.79).
- 52-week range $8.72–$27.41; today's close sits at 20% of that range, 54.5% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 14, 2026 — CBIO dips 2.6% to $12.58, a 6-month low, 3 down days in a row
- Closed at $12.58, -2.56% vs the prior close of $12.91. Day range $12.18–$13.21, opened at $12.67.
- Volume was 284.80K shares, 0.8x its 50-day average of 371.18K.
- Price is -23.9% vs its 50-day average ($16.52) and -20.3% vs its 200-day average ($15.79).
- 52-week range $8.72–$27.41; today's close sits at 21% of that range, 54.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CBIO slides 10.7% to $12.91, a 6-month low
- Closed at $12.91, -10.72% vs the prior close of $14.46. Day range $12.85–$14.67, opened at $14.46.
- Volume was 197.10K shares, 0.5x its 50-day average of 371.97K — lighter than usual.
- Price is -22.2% vs its 50-day average ($16.60) and -18.2% vs its 200-day average ($15.79).
- 52-week range $8.72–$27.41; today's close sits at 22% of that range, 52.9% below the 52-week high.
Oct 12, 2026 — CBIO slides 3.0% to $14.46
- Closed at $14.46, -3.02% vs the prior close of $14.91. Day range $14.32–$15.09, opened at $14.79.
- Volume was 153.90K shares, 0.4x its 50-day average of 374.74K — lighter than usual.
- Price is -13.1% vs its 50-day average ($16.64) and -8.4% vs its 200-day average ($15.78).
- 52-week range $8.72–$27.41; today's close sits at 31% of that range, 47.2% below the 52-week high.
Oct 9, 2026 — CBIO jumps 5.6% to $14.91
- Closed at $14.91, +5.59% vs the prior close of $14.12. Day range $14.07–$15.28, opened at $14.07.
- Volume was 347.10K shares, 0.9x its 50-day average of 373.45K.
- Price is -10.4% vs its 50-day average ($16.64) and -5.5% vs its 200-day average ($15.77).
- 52-week range $8.72–$27.41; today's close sits at 33% of that range, 45.6% below the 52-week high.
Oct 8, 2026 — CBIO jumps 4.7% to $14.12
- Closed at $14.12, +4.67% vs the prior close of $13.49. Day range $12.98–$14.61, opened at $13.39.
- Volume was 301.20K shares, 0.8x its 50-day average of 377.95K.
- Price is -15.1% vs its 50-day average ($16.64) and -10.4% vs its 200-day average ($15.76).
- 52-week range $8.72–$27.41; today's close sits at 29% of that range, 48.5% below the 52-week high.
Oct 7, 2026 — CBIO dips 0.6% to $13.49, a 6-month low on 2.9x normal volume
- Closed at $13.49, -0.59% vs the prior close of $13.57. Day range $13.27–$14.20, opened at $13.47.
- Volume was 1.05M shares, 2.9x its 50-day average of 361.64K — unusually heavy trading.
- Price is -19.0% vs its 50-day average ($16.65) and -14.3% vs its 200-day average ($15.75).
- 52-week range $8.72–$27.41; today's close sits at 26% of that range, 50.8% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — CBIO dips 2.7% to $13.57, a 6-month low
- Closed at $13.57, -2.65% vs the prior close of $13.94. Day range $13.46–$14.93, opened at $14.78.
- Volume was 492.40K shares, 1.4x its 50-day average of 357.24K.
- Price is -18.8% vs its 50-day average ($16.71) and -13.8% vs its 200-day average ($15.74).
- 52-week range $8.72–$27.41; today's close sits at 26% of that range, 50.5% below the 52-week high.
Oct 5, 2026 — CBIO dips 2.7% to $13.94, a 6-month low
- Closed at $13.94, -2.65% vs the prior close of $14.32. Day range $13.63–$14.42, opened at $14.42.
- Volume was 187.00K shares, 0.5x its 50-day average of 358.95K — lighter than usual.
- Price is -16.9% vs its 50-day average ($16.78) and -11.4% vs its 200-day average ($15.74).
- 52-week range $8.72–$27.41; today's close sits at 28% of that range, 49.1% below the 52-week high.
Oct 2, 2026 — CBIO rises 0.4% to $14.32
- Closed at $14.32, +0.42% vs the prior close of $14.26. Day range $14.07–$14.55, opened at $14.48.
- Volume was 283.30K shares, 0.8x its 50-day average of 360.25K.
- Price is -14.9% vs its 50-day average ($16.83) and -9.0% vs its 200-day average ($15.73).
- 52-week range $8.72–$27.41; today's close sits at 30% of that range, 47.8% below the 52-week high.
CBIO latest news & SEC filings
Every SEC filing by or about CBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lynch Ryan sold 240 shares at $17.90 (≈$4.30K) on Sep 16, 2026; now holds 13,631
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pinkas Jan sold 658 shares at $17.90 (≈$11.78K) on Sep 16, 2026; now holds 21,581
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Im Ellie Eunkyung sold 623 shares at $17.90 (≈$11.15K) on Sep 16, 2026; now holds 21,446
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Scalzo Richard William sold 568 shares at $17.90 (≈$10.17K) on Sep 16, 2026; now holds 19,730
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bispham Barbara Harlin sold 620 shares at $17.90 (≈$11.10K) on Sep 16, 2026; now holds 18,710
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Brumm Joshua T sold 1,610 shares at $17.90 (≈$28.82K) on Sep 16, 2026; now holds 279,602
- Brumm Joshua T sold 7,837 shares at $16.71 (≈$130.96K) on Sep 18, 2026; now holds 271,765
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Jul 30, 2026 · Form POS AM — POS AM filing
POS AM filing
Jul 30, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$24.84M (prior year -$21.79M) (loss widened vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 20, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CBIO
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Jul 14, 2026, Apr 29, 2026, Feb 26, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.42% (largest 13.7%). That is a volatile stock.
- Liquidity: about 376.23K shares (≈$4.45M) trade per day on average.
- 52-week position: $11.84 vs a range of $8.72–$27.41 (17% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:100 on Jun 16, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jonathan Mcneill sold 3,839 shares on Sep 18, 2026.
- Latest filings: 8-K Oct 15, 2026; 10-Q Jul 30, 2026; 8-K Jul 30, 2026.
- Share count: 37.14M shares outstanding (Jul 27, 2026), +167.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 12.73 | 12.73 | 11.78 | 11.84 | 208.15K |
| Oct 15, 2026 | 12.62 | 13.19 | 12.31 | 12.48 | 295.90K |
| Oct 14, 2026 | 12.67 | 13.21 | 12.18 | 12.58 | 284.80K |
| Oct 13, 2026 | 14.46 | 14.67 | 12.85 | 12.91 | 197.10K |
| Oct 12, 2026 | 14.79 | 15.09 | 14.32 | 14.46 | 153.90K |
| Oct 9, 2026 | 14.07 | 15.28 | 14.07 | 14.91 | 347.10K |
| Oct 8, 2026 | 13.39 | 14.61 | 12.98 | 14.12 | 301.20K |
| Oct 7, 2026 | 13.47 | 14.20 | 13.27 | 13.49 | 1.05M |
| Oct 6, 2026 | 14.78 | 14.93 | 13.46 | 13.57 | 492.40K |
| Oct 5, 2026 | 14.42 | 14.42 | 13.63 | 13.94 | 187.00K |
| Oct 2, 2026 | 14.48 | 14.55 | 14.07 | 14.32 | 283.30K |
| Oct 1, 2026 | 14.61 | 14.73 | 14.10 | 14.26 | 300.90K |
| Sep 30, 2026 | 14.89 | 15.00 | 14.23 | 14.59 | 289.50K |
| Sep 29, 2026 | 14.66 | 15.62 | 14.16 | 14.76 | 684.60K |
| Sep 28, 2026 | 13.93 | 14.76 | 13.50 | 14.53 | 290.90K |
| Sep 25, 2026 | 14.29 | 14.46 | 13.66 | 13.99 | 228.70K |
| Sep 24, 2026 | 14.04 | 14.48 | 13.44 | 14.24 | 568.80K |
| Sep 23, 2026 | 16.37 | 16.47 | 13.70 | 14.19 | 727.70K |
| Sep 22, 2026 | 16.48 | 16.65 | 16.01 | 16.44 | 257.60K |
| Sep 21, 2026 | 16.93 | 17.04 | 15.76 | 16.25 | 375.80K |
About Crescent Biopharma
Crescent Biopharma (CBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: Cayman Islands. Fiscal year ends December 31. SEC CIK 1253689.
CBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Alexandra Balcom | Director | Jun 3, 2026 |
| Joshua T Brumm | Chief Executive Officer | Sep 18, 2026 |
| Funds Management Llc Fairmount | Director | Jul 20, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | Jul 20, 2026 |
| Peter Evan Harwin | Director | Jul 20, 2026 |
| Tomas Kiselak | Director | Jul 20, 2026 |
| David Charles Lubner | Director | Jun 3, 2026 |
| Susan Moran | Director | Jun 3, 2026 |
| Jonathan Violin | Director | Jun 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Barbara Harlin Bispham | See Remarks | Sep 18, 2026 |
| Joshua T Brumm | Chief Executive Officer | Sep 18, 2026 |
| Christopher Grant Doughty | Chief Business Officer | Dec 17, 2025 |
| Ellie Eunkyung Im | Chief Medical Officer | Sep 18, 2026 |
| Ryan Lynch | See Remarks | Sep 18, 2026 |
| Jonathan Mcneill | President and COO | Sep 18, 2026 |
| Jan Pinkas | Chief Scientific Officer | Sep 18, 2026 |
| Richard William Scalzo | Chief Financial Officer | Sep 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 18, 2026 | Jonathan Mcneill | Sale | 3,839 | $16.71 |
| Sep 18, 2026 | Jonathan Mcneill | Sale | 3,839 | $16.71 |
| Sep 18, 2026 | Jonathan Mcneill | Sale | 3,839 | $16.71 |
| Sep 18, 2026 | Jonathan Mcneill | Sale | 3,839 | $16.71 |
| Sep 18, 2026 | Joshua T Brumm | Sale | 7,837 | $16.71 |
| Sep 18, 2026 | Joshua T Brumm | Sale | 7,837 | $16.71 |
| Sep 18, 2026 | Joshua T Brumm | Sale | 7,837 | $16.71 |
| Sep 18, 2026 | Joshua T Brumm | Sale | 7,837 | $16.71 |
| Sep 16, 2026 | Jonathan Mcneill | Sale | 731 | $17.90 |
| Sep 16, 2026 | Jonathan Mcneill | Sale | 731 | $17.90 |
| Sep 16, 2026 | Jonathan Mcneill | Sale | 731 | $17.90 |
| Sep 16, 2026 | Jonathan Mcneill | Sale | 731 | $17.90 |
| Sep 16, 2026 | Richard William Scalzo | Sale | 568 | $17.90 |
| Sep 16, 2026 | Richard William Scalzo | Sale | 568 | $17.90 |
| Sep 16, 2026 | Richard William Scalzo | Sale | 568 | $17.90 |
CBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $10.84M | $-153.94M | — | $-71.53M |
| Dec 31, 2024 | — | $-37.88M | -0.59 | $-31.10M |
| Dec 31, 2023 | — | $-36.90M | -0.58 | $-34.88M |
| Dec 31, 2022 | — | $-46.69M | -0.89 | $-46.46M |
| Dec 31, 2021 | — | $-63.43M | -1.23 | $-57.49M |
Latest balance sheet: total assets $182.76M, total liabilities $19.50M, cash $171.59M (as of Jun 30, 2026).
CBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $15.02 |
| Jul 14, 2026 | 8-K Item 2.02 (results) | $15.31 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $20.94 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $12.35 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $13.10 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $12.42 |
| Jun 18, 2025 | 8-K Item 2.02 (results) | $14.62 |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 3, 2023 | 8-K Item 2.02 (results) | — |
| Aug 2, 2023 | 8-K Item 2.02 (results) | — |
| May 3, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.